WuXi PharmaTech (WX) Misses Q2 EPS by 1c, Reconfirms FY Rev Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to WuXi PharmaTech (WX) Misses Q2 EPS by 1c, Reconfirms FY Rev Guidance
August 17, 2015 7:36 AM EDT
William Blair downgraded WuXi PharmaTech (NYSE: WX) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on WuXi PharmaTech click here. For more ratings news on WuXi PharmaTech click here.
Shares of WuXi PharmaTech closed at $43.86 yesterday.
...
More
August 14, 2015 6:36 AM EDT
WuXi PharmaTech (NYSE: WX) announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with New WuXi Life Science Limited ("Parent") and WuXi Merger Limited ("Merger Sub"), a wholly owned subsidiary of Parent.
Pursuant to the Merger Agreement, Parent will acquire the Company for cash consideration equal to US$5.75 per ordinary share of the Company (each, a "Share") and US$46 per American Depositary Share of the Company, each representing eight Shares (each, an "ADS"), or approximately US$3.3 billion in aggregate cash consideration. This represents a 16.5%... More
